Dmytro Kharkov

Allogene Therapeutics to present pipeline and strategy update at Jefferies Global Healthcare Conference

Allogene Therapeutics to present pipeline and strategy update at Jefferies Global Healthcare Conference
Allogene pipeline update in New York

Allogene Therapeutics is set to participate in the Jefferies Global Healthcare Conference in New York, where the company will provide an update on its investigational pipeline and corporate strategy.

The event highlights Allogene Therapeutics' continued engagement with the investment community and reinforces its commitment to advancing allogeneic cell therapy platforms. Webcast information is available in the Investors section of the company's website.

Allogene Therapeutics recently shared pipeline and corporate strategy updates during the TD Cowen Oncology Innovation Summit webcast. The company also introduced ALLO-329, a next-generation cell therapy candidate for autoimmune diseases, with an approach aimed at reducing lymphodepletion risks. These developments reflect Allogene’s ongoing efforts to advance its clinical portfolio.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.